

### **NanoMedicine and NanoDiagnostics: Current State of Global R&D, Investment, and Future Outlook**

**Dr. Mostafa Analoui**

Head of Healthcare and Life Sciences

The Livingston Group

New York, NY

#### Abstract

R&D in Healthcare and Life Sciences are greatly impacted by recent advances in conventional and emerging technologies, especially in understanding of disease, drug discovery, and novel diagnostics. Nanotechnology is being positioned as one of the critical class of such technologies, with broad reaching impacts in Life Sciences R&D, including drug discovery, formulation, delivery, clinical assessment and monitoring. Additionally, there is significant emerging need for high-precision and rapid diagnostics for streamlining and customizing treatment and disease management.

Nanotechnology's recent impact includes significant development in formulation of existing drug, novel delivery mechanism and new diagnostics. In the long horizon, there is a promise of new class of drugs designed around nanobiotechnology approach from ground up to address significant unmet medical needs.

This presentation provides an overview of key R&D and product developments around use of nanotechnology in drug discovery, diagnostics and medical devices. It will also offer a snapshot of historical trends in investment, M&A and exits in this area, as well as what is shaping capital markets, especially in light of recent turmoil in the financial markets.

Dr. Analoui will also offer an outlook of emerging global patterns, role of major pharmaceutical, diagnostic and medical device players in future R&D, venture investments and M&A deals.